-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3718 Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure

Acute Lymphoblastic Leukemia: Clinical Studies
Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
Monday, December 7, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Punit L Jain, MD1*, Koji Sasaki, MD2, Hagop Kantarjian, MD3, Farhad Ravandi, MD4, Jorge E. Cortes, MD5, Guillermo Garcia-Manero, MD5, Prithviraj Bose, MD6*, Naval Daver, MD7, Tapan Kadia, MD5, Srdan Verstovsek, MD6, Marina Konopleva, MD, PhD6, Nitin Jain, MD6, Guillermo Bravo Montalban, MD8*, Sherry Pierce, BSN, BA6* and Elias Jabbour6

1Department of Leukemia, M D Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX
8M D Anderson Cancer Center, University of Texas, Houston

Introduction: Intensive induction-consolidation chemotherapy achieves high rates of complete response (CR) in 90% of patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, almost a half of the patients relapse and their outcome after frontline chemotherapy failure is essentially poor.

Methods: We retrospectively reviewed 463 patients with newly diagnosed Philadelphia-negative ALL from June 2002 to February 2015 at our institution. Overall survival was defined as the time interval from the date of relapse to the date of death. Kaplan-Meier method was used for survival analysis.

Results: Of the 463 patients, 155 (33%) relapsed. Data on salvage therapy and long term follow-up was available in 76 patients (17%). The median time to relapse was 15 months (range, 1-111 months). The median number of salvage regimens administered was 1 (range, 1-7). Overall, 76 patients received at least 1 salvage therapy. Thirty (39%) patients received at least 2 salvage regimens and 18 (24%) received 3 or more salvage regimens. Baseline patient characteristics are summarized in the table 1. Median follow-up after frontline therapy failure was 16 months. The median survival after relapse was 8.3 months with the 1- year and 2-year survival rates being 46 % and 28% respectively.

Salvage 1 included augmented HCVAD [n=13; 7/13 responses (6 CR, 1 CRp) for a median of 6 months], asparaginase based therapies [n=6; 2/6 response (2 CR) for a median of 2 months], monoclonal antibodies (MAB), blinatumomab, inotuzumab ozogamicin  [n=19; 11/19 responses (6 CR, 5 CRp) for a median of 7 months], HCVAD + anti-CD20 antibody [n=11; 8/11 responses (5 CR, 3 CRp) for a median of 6 months], Miscellaneous [n=22; 2/22 responses (2 CR)] and HCVAD [n=5; 1/5 response (1 CR) for 1 month]. The overall response rate to Salvage 1 was 41% (22 CR, 9 CRp) for a median of 6 months. Nineteen (25%) patients received subsequent allogeneic stem cell transplantation (ASCT); 11 of them are alive with a median of 2 years with 7 of them in CR.

Thirty patients received a second salvage regimen; the most commonly used one consisted of MAB (blinatumomab; inotuzumomab ozogamicin) [n=8; 4/8 responses (2 CR, 2 CRp) for a median of 2.5 months]. The overall response rate to salvage 2 was 30% (6 CR, 3 CRp) for a median of 3 months.

At the last follow-up, overall 23 patients remained alive, 9 of them in CR.

Conclusions: Outcome of patients with Philadelphia-negative ALL post frontline therapies failure is poor with a median survival of only 8.3 months. Though some salvage therapies can induce remissions, response durations are limited. Stem cell transplant after remission offers a potential of long term cure. These patients should be referred to clinical trials.

Table 1. Baseline characteristics and outcome of adults with relapsed B cell ALL (Ph -)

who received salvage chemotherapy :

N (%)/ Median [range]

N= 76

Age (years)

36 (18-86)

Age ³ 60

15 (20)

Male

46 (61)

PS 2-3

9 (12)

WBC at diagnosis (x 109/L)

7.2 [1-602]

CD20 positivity at diagnosis

24 (32)

Cytogenetic Abnormality

   Diploid

22 (29)

   Hypodiploid

8 (11)

   Hyperdiploid

12 (16)

   t(4;11)

5 (7)

   Miscellaneous

28 (37)

Type of Induction chemotherapy, No. (%)

   Augmented BFM

28 (37)

   HCVAD

21 (28)

   HCVAD + anti-CD20 antibody

27 (35)

Overall response to frontline therapy

   CR

73 (96)

   CR without platelet count recovery

2 (3)

   Partial response

1 (1)

Median response duration, (month)

15[1-63]

Response duration <12 months

35 (46)

Complete response to salvage chemotherapy

   S1

31/76 (41)

   S2

9/30 (30)

   S3 or more

   3/18 (17)

Allogeneic stem cell transplant

19 (25)

                Figure 1. Overall survival

Disclosures: Cortes: Novartis: Consultancy , Research Funding ; Pfizer: Consultancy , Research Funding ; BerGenBio AS: Research Funding ; BMS: Consultancy , Research Funding ; Teva: Research Funding ; Ariad: Consultancy , Research Funding ; Astellas: Consultancy , Research Funding ; Ambit: Consultancy , Research Funding ; Arog: Research Funding ; Celator: Research Funding ; Jenssen: Consultancy . Daver: ImmunoGen: Other: clinical trial , Research Funding . Konopleva: Novartis: Research Funding ; AbbVie: Research Funding ; Stemline: Research Funding ; Calithera: Research Funding ; Threshold: Research Funding .

*signifies non-member of ASH